Contineum Therapeutics, Inc. (NASDAQ: CTNM) reported Q2 EPS of ($0.62), $0.34 worse than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Contineum Therapeutics, Inc. (CTNM) click here.